Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp.

0.26
USD
-0.02
(-6.21%)
-0.16EPS
25.37MMarket Cap

Total Valuation

USD

As of June 30, 2026, Medicenna Therapeutics Corp. carries a market capitalization of 25.37M, placing it among publicly traded companies globally. Its enterprise value stands at 21.44M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap25.37M
Enterprise Value21.44M

Important Dates

Medicenna Therapeutics Corp.'s next confirmed earnings release is scheduled for November 16, 2026.

Earnings Date11/16/2026

Share Statistics

As of June 30, 2026, Medicenna Therapeutics Corp. has 92.30M shares outstanding.

Shares Outstanding92.30M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio21.52
P/TBV Ratio22.12
P/FCF Ratio-1.75
P/OCF Ratio-1.75

Financial Position

As of June 30, 2026, Medicenna Therapeutics Corp. maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities.

Current Ratio1.25
Quick Ratio1.11
Debt / Equity6.22

Financial Efficiency

Over the twelve months ended June 30, 2026, Medicenna Therapeutics Corp. posted a negative return on equity (ROE) of -227.57, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -119.69, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 19.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-227.57
Return on Assets (ROA)-119.69
Employee Count19.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Medicenna Therapeutics Corp.'s stock has declined approximately 74.72% over the past 52 weeks. The 50-day moving average sits at 0.30, while the 200-day moving average is 0.39.

52-Week Price Change-74.72%
50-Day Moving Average0.30
200-Day Moving Average0.39

Income Statement

USD

Over the twelve months ended June 30, 2026, Medicenna Therapeutics Corp. generated - - in revenue and converted that into -13.08M in net income, yielding earnings per share of -0.16. EBITDA reached -15.71M, while operating income came in at -15.75M.

Operating Income-15.75M
Pretax Income-13.08M
Net Income-13.08M
EBITDA-15.71M
EBIT-15.75M
Earnings Per Share (EPS)-0.16

Balance Sheet

USD

As of June 30, 2026, Medicenna Therapeutics Corp. holds 4.01M in cash and equivalents against 73,280.21 in total debt, resulting in a net debt position of -4.01M. Total book value stands at 1.18M, with working capital of 1.15M providing operational flexibility.

Cash & Cash Equivalents4.01M
Total Debt73,280.21
Net Debt-4.01M
Equity (Book Value)1.18M
Book Value Per Share0.01
Working Capital1.15M

Cash Flow

USD

Medicenna Therapeutics Corp. produced -13.25M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -13.25M - equivalent to -0.16 per share.

Operating Cash Flow-13.25M
Free Cash Flow-13.25M
FCF Per Share-0.16

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -57.24: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.61, meaning Medicenna Therapeutics Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-10.61
FCF Yield-57.24

Stock Splits

Medicenna Therapeutics Corp.'s most recent stock split took place on March 3, 2017 with a 14:1 split ratio.

Last Split Date3/3/2017
Split Ratio14:1

Scores

As of June 30, 2026, Medicenna Therapeutics Corp. has an Altman Z-Score of -29.66, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-29.66